Key Drivers
- Strong Gross Margin
- Quarterly Profit Drop
- Higher Valuation Risk
AIAI Summary
COO is now more of a cash-generative, event-driven value-unlock story than a plain medtech compounder, with the CooperSurgical strategic review and strong free cash flow supporting upside, but the stock already prices in a lot of success and remains exposed to APAC कमजोरी, litigation overhang, and unstable margins.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Gross Margin
- •Quarterly Profit Drop
- •Higher Valuation Risk
Cooper still generates strong cash flow and healthy gross margins, but recent quarterly profitability and liquidity weakened, making its rich valuation look hard to justify.
Price Behavior
Key Price Behavior Insights:
- •Breakout confirmed
- •Higher-high trend
- •Overbought momentum
COO remains in a strong short-term uptrend after breaking above $71.00–$72.00 to a fresh high near $74.20, but the rapid move leaves it overbought and vulnerable to a near-term pause or consolidation.
Rapid climb from $60.34 to $74.20 in about a month suggests short-term volatility risk
Sentiment & News
Key News Insights:
- •Demand resilience
- •Regional weakness
- •ESG disclosure
CooperCompanies remains supported by strong demand in myopia-control and fertility businesses, but Asia-Pacific weakness, litigation/cost pressures, and insider selling keep execution risk in focus despite a recent share gain.
The news is modestly positive overall, with durable growth drivers offset by operational and geographic risks that may limit upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings